Lilly will acquire our mutant-selective PI3Kα inhibitor program, led by STX-478, a promising, next-generation treatment currently in Phase 1/2 trials for breast cancer and other advanced solid ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

To further bolster its pursuit of becoming a leading player in the oncology market, Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion ...

Scorpion currently has STX-478, a once-daily oral medicine with a mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid ...